🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Alkem Laboratories Limited ALKEM NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.alkemlabs.com
Company Profile ↓
₹5,190.00
+1.79% 1Y
Mkt Cap₹62,054.24 Cr
P/E26.96
P/B4.86
Div. Yield0.36%
52W High₹5,832.46
52W Low₹5,098.70
Book Value₹1,155.87
EPS (TTM)₹192.51

Company Overview

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti – infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 16.7%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 18.6%.

Consistent Profit Growth

Net profit has compounded at 32.7% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 27.0, below the sector median of 41.6.

Healthy Margins

Maintains a net profit margin of 15.8%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.15.

Recent Developments

  • Mar 2026 Revenue of ₹14,532.34 Cr (+13.5% YoY); net profit ₹2,301.80 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +13.5%, earnings +6.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.3%, profit CAGR 32.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.30%
1 Year:13.49%

Compounded Profit Growth

5 Years:32.74%
1 Year:6.30%

Stock Price Performance

1 Year:+1.79%
6 Months:-5.98%
3 Months:-2.92%
1 Month:-7.11%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 12% of range
₹5,098.70 ₹5,832.46
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)31.73 · Neutral
Price Performance
1M-7.11%
3M-2.92%
6M-5.98%
1Y+1.79%
Valuation vs Sector

P/E of 26.96 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 32.7% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
26.96
Industry PE
41.64
Forward P/E
22.94
PEG Ratio
-
Book Value
₹1,155.87
Price to Book
4.86
P/S
4.57
EV/EBITDA
22.57
Dividend Yield
0.36%

Growth (CAGR)

Revenue 5Y
8.30%
Profit 5Y
32.74%
Revenue (YoY)
13.49%
Earnings (YoY)
6.30%

Profitability & Returns

ROCE
18.56%
ROE
16.66%
ROA
11.03%
Profit Margin
15.84%
Op Margin
18.23%
Gross Margin
64.22%
EPS (Latest Qtr)
₹19.77
EPS (TTM)
₹192.51

Balance Sheet & Liquidity

Debt/Equity
0.15
Quick Ratio
1.86
Current Ratio
2.55
Debt
₹2,047.16 Cr
Total Assets
₹20,872.97 Cr
Current Assets
₹12,210.52 Cr
Working Capital
₹7,427.82 Cr

Ownership

Promoter Holding
62.44%
Chg in Prom Hold
-
FII / Inst Holding
27.53%
Chg in FII Hold
0.21%

Financial Snapshot

Enterprise Value
₹62,054.24 Cr
Total Revenue (TTM)
₹14,532.34 Cr
EBITDA
₹3,368.92 Cr
Free Cash Flow
₹1,345.77 Cr
Operating Cash Flow
₹1,963.03 Cr
Shares Outstanding
₹11.96 Cr
Gross Margin
64.22%
Payout Ratio
26.49%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ALKEM Alkem Laboratories Limited NIFTY_MIDNSEPHARMA 5,190.00 26.96 ₹62,054.24 Cr 0.36% 18.56% 16.66% 8.30% 32.74%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 2,903.00 Cr2,968.00 Cr3,440.00 Cr3,324.00 Cr2,936.00 Cr3,032.00 Cr3,415.00 Cr3,374.00 Cr3,143.75 Cr3,371.14 Cr4,000.99 Cr3,736.82 Cr3,603.32 Cr
Cost of Revenue --------1,279.28 Cr1,171.16 Cr1,401.03 Cr1,272.71 Cr1,247.87 Cr
Gross Profit --------1,864.47 Cr2,199.98 Cr2,599.96 Cr2,464.11 Cr2,355.45 Cr
Operating Expenses 2,549.00 Cr2,579.00 Cr2,693.00 Cr2,616.00 Cr2,534.00 Cr2,423.00 Cr2,662.00 Cr2,615.00 Cr1,585.67 Cr1,548.61 Cr1,772.80 Cr1,731.12 Cr1,943.82 Cr
Operating Income 275.00 Cr317.00 Cr673.00 Cr638.00 Cr319.00 Cr529.00 Cr674.00 Cr674.00 Cr278.80 Cr651.37 Cr827.16 Cr732.99 Cr411.63 Cr
EBITDA 353.00 Cr389.00 Cr747.00 Cr708.00 Cr402.00 Cr609.00 Cr753.00 Cr759.00 Cr537.25 Cr888.47 Cr1,024.46 Cr918.31 Cr582.49 Cr
Interest Expense 29.00 Cr30.00 Cr30.00 Cr25.00 Cr27.00 Cr29.00 Cr28.00 Cr36.00 Cr28.42 Cr29.78 Cr35.02 Cr42.10 Cr53.88 Cr
Pretax Income 212.00 Cr353.00 Cr648.00 Cr655.00 Cr367.00 Cr619.00 Cr780.00 Cr731.00 Cr396.34 Cr771.01 Cr895.83 Cr781.20 Cr422.85 Cr
Tax Provision 144.16 Cr63.54 Cr32.40 Cr52.40 Cr62.39 Cr68.09 Cr78.00 Cr87.72 Cr73.33 Cr102.69 Cr116.23 Cr127.67 Cr171.17 Cr
Net Income 68.00 Cr288.00 Cr615.00 Cr604.00 Cr304.00 Cr550.00 Cr702.00 Cr641.00 Cr305.86 Cr664.26 Cr765.06 Cr636.02 Cr236.46 Cr
Diluted EPS 5.9423.9851.9049.7624.5545.6057.6052.3425.5755.5663.9953.1919.77

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 3,674.00 Cr4,905.00 Cr5,688.00 Cr6,401.00 Cr7,357.00 Cr8,344.00 Cr8,865.00 Cr-11,440.35 Cr12,439.24 Cr12,804.62 Cr14,532.34 Cr
Cost of Revenue --------4,982.32 Cr5,031.77 Cr4,857.55 Cr5,199.34 Cr
Gross Profit --------6,458.03 Cr7,407.47 Cr7,947.07 Cr9,333.00 Cr
Operating Expenses 3,248.00 Cr4,038.00 Cr4,687.00 Cr5,392.00 Cr6,237.00 Cr6,868.00 Cr6,920.00 Cr-5,123.86 Cr5,422.61 Cr5,762.84 Cr6,683.87 Cr
Operating Income 356.00 Cr773.00 Cr900.00 Cr866.00 Cr927.00 Cr1,223.00 Cr1,670.00 Cr-1,334.17 Cr1,984.86 Cr2,184.23 Cr2,649.13 Cr
EBITDA 427.00 Cr866.00 Cr1,001.00 Cr1,009.00 Cr1,120.00 Cr1,476.00 Cr1,945.00 Cr-1,708.94 Cr2,418.14 Cr2,971.43 Cr3,368.92 Cr
Interest Expense 81.00 Cr71.00 Cr45.00 Cr55.00 Cr55.00 Cr65.00 Cr59.00 Cr-93.75 Cr95.71 Cr87.24 Cr115.97 Cr
Pretax Income 451.00 Cr928.00 Cr965.00 Cr926.00 Cr955.00 Cr1,260.00 Cr1,842.00 Cr-1,304.77 Cr2,023.13 Cr2,527.03 Cr2,870.89 Cr
Tax Provision 58.63 Cr176.32 Cr57.90 Cr287.06 Cr181.45 Cr113.40 Cr221.04 Cr-297.96 Cr211.67 Cr311.03 Cr517.76 Cr
Net Income 392.00 Cr752.00 Cr905.00 Cr638.00 Cr774.00 Cr1,149.00 Cr1,618.00 Cr-984.17 Cr1,795.77 Cr2,165.48 Cr2,301.80 Cr
Diluted EPS 32.7562.0274.6152.7763.6194.26132.57-82.31150.19181.11192.51

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 5,291.00 Cr5,534.00 Cr6,568.00 Cr7,664.00 Cr8,208.00 Cr9,946.00 Cr11,519.00 Cr-13,756.65 Cr15,574.90 Cr17,691.10 Cr20,872.97 Cr
Current Assets --------8,729.68 Cr10,411.58 Cr10,945.82 Cr12,210.52 Cr
Cash & Equivalents --------273.80 Cr455.07 Cr304.14 Cr247.91 Cr
Inventory --------2,607.53 Cr2,661.18 Cr2,922.41 Cr3,333.22 Cr
Receivables --------2,132.18 Cr2,252.81 Cr2,466.25 Cr2,979.11 Cr
Total Liabilities --------4,321.65 Cr4,860.50 Cr5,257.47 Cr6,524.04 Cr
Current Liabilities --------3,707.14 Cr3,994.55 Cr3,966.96 Cr4,782.70 Cr
Long Term Debt --------040.00 Cr310.91 Cr492.45 Cr
Total Debt 1,306.00 Cr658.00 Cr659.00 Cr998.00 Cr944.00 Cr1,616.00 Cr1,707.00 Cr-1,396.68 Cr1,418.41 Cr1,380.90 Cr2,047.16 Cr
Total Equity 2,999.00 Cr3,692.00 Cr4,468.00 Cr4,864.00 Cr5,439.00 Cr6,161.00 Cr7,377.00 Cr-9,045.29 Cr10,312.06 Cr11,984.87 Cr13,820.10 Cr
Shares Outstanding --------11.96 Cr11.96 Cr11.96 Cr11.96 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 325.00 Cr726.00 Cr471.00 Cr266.00 Cr780.00 Cr585.00 Cr1,265.00 Cr-1,682.50 Cr1,948.07 Cr1,912.84 Cr1,963.03 Cr
Investing Cash Flow -235.00 Cr205.00 Cr-294.00 Cr-351.00 Cr-318.00 Cr-737.00 Cr-995.00 Cr-112.84 Cr-1,008.50 Cr-1,298.76 Cr-1,667.21 Cr
Financing Cash Flow -52.00 Cr-927.00 Cr-138.00 Cr85.00 Cr-379.00 Cr79.00 Cr-272.00 Cr--1,760.82 Cr-1,145.01 Cr-810.99 Cr-503.40 Cr
Capital Expenditure -135.00 Cr-254.00 Cr-634.00 Cr-677.00 Cr-527.00 Cr-348.00 Cr-149.00 Cr--232.91 Cr-259.29 Cr-675.62 Cr-617.26 Cr
Free Cash Flow 190.00 Cr472.00 Cr-163.00 Cr-411.00 Cr253.00 Cr237.00 Cr1,116.00 Cr-1,449.59 Cr1,688.78 Cr1,237.22 Cr1,345.77 Cr
Net Change in Cash 39.00 Cr3.00 Cr40.00 Cr082.00 Cr-73.00 Cr-2.00 Cr-34.52 Cr-205.44 Cr-196.91 Cr-207.58 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------56.4%59.5%62.1%64.2%
Operating Margin % 9.7%15.8%15.8%13.5%12.6%14.7%18.8%-11.7%16.0%17.1%18.2%
Net Margin % 10.7%15.3%15.9%10.0%10.5%13.8%18.3%-8.6%14.4%16.9%15.8%
ROE % 13.1%20.4%20.3%13.1%14.2%18.6%21.9%-10.9%17.4%18.1%16.7%
ROCE % --------13.3%17.1%15.9%16.5%

Shareholding Pattern

Insiders
62.44%
Institutions
27.53%
Public Float
73.32%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALKEM

Yahoo Finance Sat, 15 Aug 2026

Alkem Laboratories Ltd (BOM:539523) (Q1 2027) Earnings Call Highlights: Robust Revenue Growth ...

Alkem Laboratories Ltd (BOM:539523) reports 11% revenue growth and strong India market outperformance, but faces net profit decline and US regulatory challenges.

Yahoo Finance Fri, 29 May 2026

Alkem Laboratories Ltd (BOM:539523) Q4 2026 Earnings Call Highlights: Record Profitability and ...

Alkem Laboratories Ltd (BOM:539523) reports a 14.6% revenue growth and strategic advancements despite facing global challenges.

Yahoo Finance Fri, 01 May 2026

Chlorpheniramine Maleate - Global Market Insights, Competitive Landscape & Industry Forecast to 2033 Featuring Viatris, Alkem Labs, Merck & Co., Johnson & Johnson, Capellon Pharma and More

The chlorpheniramine maleate market is poised for growth due to rising allergic conditions, OTC antihistamine awareness, and pharmaceutical innovationDublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "Chlorpheniramine Maleate Market Insights, Co…

Yahoo Finance ue, 09 Jun 2026

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was valued at approximately USD 491.35 Billion in 2024 and is expect…

Yahoo Finance Mon, 23 Mar 2026

India Opened the Floodgates on Weight-Loss Generics

Indian pharma companies are releasing over 50 generic versions of Ozempic and Wegovy at eye-watering prices of $14 a month.

Yahoo Finance Wed, 04 Mar 2026

Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements

Esperion Therapeutics Inc (NASDAQ:ESPR) is among the best NASDAQ penny stocks to buy according to analysts. On February 17, Esperion Therapeutics Inc (NASDAQ:ESPR) struck a deal with Alkem Laboratories regarding the sale of rival generic dr…

ALKEM — Frequently Asked Questions

What is the current share price of Alkem Laboratories Limited (ALKEM)?

As of 2026-09-08 04:53 IST, Alkem Laboratories Limited (ALKEM) trades at ₹5,190.00 on NSE. Its 52-week range is ₹5,098.70 to ₹5,832.46.

What is the market capitalisation of ALKEM?

Alkem Laboratories Limited (ALKEM) has a market capitalisation of ₹62,054.24 Cr on NSE.

What is the P/E ratio of ALKEM?

ALKEM trades at a trailing price-to-earnings (P/E) ratio of 26.96. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 4.86.

Does ALKEM pay a dividend?

Alkem Laboratories Limited (ALKEM) currently offers a dividend yield of 0.36%.

What is the return on equity (ROE) of ALKEM?

ALKEM has a return on equity (ROE) of 16.66%. Its return on capital employed (ROCE) is 18.56%.

Is ALKEM a good stock to buy?

This page provides a data-driven analysis of Alkem Laboratories Limited (ALKEM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space